Sangamo Therapeutics (SGMO) Accumulated Expenses (2016 - 2025)
Historic Accumulated Expenses for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $17.1 million.
- Sangamo Therapeutics' Accumulated Expenses rose 4735.71% to $17.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year increase of 4735.71%. This contributed to the annual value of $14.6 million for FY2024, which is 3814.64% down from last year.
- Per Sangamo Therapeutics' latest filing, its Accumulated Expenses stood at $17.1 million for Q3 2025, which was up 4735.71% from $15.4 million recorded in Q2 2025.
- In the past 5 years, Sangamo Therapeutics' Accumulated Expenses registered a high of $23.6 million during Q4 2023, and its lowest value of $11.6 million during Q3 2024.
- In the last 5 years, Sangamo Therapeutics' Accumulated Expenses had a median value of $17.1 million in 2025 and averaged $16.9 million.
- Per our database at Business Quant, Sangamo Therapeutics' Accumulated Expenses skyrocketed by 6014.9% in 2021 and then plummeted by 3814.64% in 2024.
- Quarter analysis of 5 years shows Sangamo Therapeutics' Accumulated Expenses stood at $20.8 million in 2021, then increased by 3.2% to $21.5 million in 2022, then increased by 9.52% to $23.6 million in 2023, then crashed by 38.15% to $14.6 million in 2024, then increased by 17.68% to $17.1 million in 2025.
- Its Accumulated Expenses stands at $17.1 million for Q3 2025, versus $15.4 million for Q2 2025 and $14.0 million for Q1 2025.